<SEC-DOCUMENT>0001415889-24-009073.txt : 20240325
<SEC-HEADER>0001415889-24-009073.hdr.sgml : 20240325
<ACCEPTANCE-DATETIME>20240325204009
ACCESSION NUMBER:		0001415889-24-009073
CONFORMED SUBMISSION TYPE:	4
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20240321
FILED AS OF DATE:		20240325
DATE AS OF CHANGE:		20240325

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Scheiner Zachary
		CENTRAL INDEX KEY:			0001816523
		ORGANIZATION NAME:           	

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40532
		FILM NUMBER:		24780700

	MAIL ADDRESS:	
		STREET 1:		200 BERKELEY STREET
		STREET 2:		18TH FLOOR
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02116

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			LENZ Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001815776
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				844867570
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		445 MARINE VIEW AVE SUITE 320
		CITY:			DEL MAR
		STATE:			CA
		ZIP:			92014
		BUSINESS PHONE:		858-925-7000

	MAIL ADDRESS:	
		STREET 1:		445 MARINE VIEW AVE SUITE 320
		CITY:			DEL MAR
		STATE:			CA
		ZIP:			92014

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Graphite Bio, Inc.
		DATE OF NAME CHANGE:	20210312

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Integral Medicines, Inc.
		DATE OF NAME CHANGE:	20200622
</SEC-HEADER>
<DOCUMENT>
<TYPE>4
<SEQUENCE>1
<FILENAME>form4-03262024_120359.xml
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0508</schemaVersion>

    <documentType>4</documentType>

    <periodOfReport>2024-03-21</periodOfReport>

    <issuer>
        <issuerCik>0001815776</issuerCik>
        <issuerName>LENZ Therapeutics, Inc.</issuerName>
        <issuerTradingSymbol>LENZ</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001816523</rptOwnerCik>
            <rptOwnerName>Scheiner Zachary</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O RA CAPITAL MANAGEMENT</rptOwnerStreet1>
            <rptOwnerStreet2>200 BERKELEY STREET, 18TH FLOOR</rptOwnerStreet2>
            <rptOwnerCity>BOSTON</rptOwnerCity>
            <rptOwnerState>MA</rptOwnerState>
            <rptOwnerZipCode>02116</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>true</isDirector>
            <isOfficer>false</isOfficer>
            <isTenPercentOwner>false</isTenPercentOwner>
            <isOther>false</isOther>
            <officerTitle></officerTitle>
            <otherText></otherText>
        </reportingOwnerRelationship>
    </reportingOwner>

    <aff10b5One>0</aff10b5One>

    <nonDerivativeTable></nonDerivativeTable>

    <derivativeTable>
        <derivativeTransaction>
            <securityTitle>
                <value>Stock Option (right to buy)</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <value>15.05</value>
            </conversionOrExercisePrice>
            <transactionDate>
                <value>2024-03-21</value>
            </transactionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>A</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
            </transactionCoding>
            <transactionAmounts>
                <transactionShares>
                    <value>27000</value>
                </transactionShares>
                <transactionPricePerShare>
                    <value>0</value>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>A</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <exerciseDate>
                <footnoteId id="F1"/>
            </exerciseDate>
            <expirationDate>
                <value>2034-03-20</value>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Common Stock</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>27000</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>27000</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                    <footnoteId id="F2"/>
                </directOrIndirectOwnership>
                <natureOfOwnership>
                    <value></value>
                </natureOfOwnership>
            </ownershipNature>
        </derivativeTransaction>
    </derivativeTable>

    <footnotes>
        <footnote id="F1">Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2024 Equity Incentive Plan) through each applicable date, one thirty-sixth (1/36th) of the shares subject to the option shall vest each month following the Vesting Commencement Date on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). &quot;Vesting Commencement Date&quot; shall mean March 21, 2024.</footnote>
        <footnote id="F2">Under the Reporting Person's arrangement with RA Capital Management, L.P. (the &quot;Adviser&quot;), the Reporting Person holds the option for the benefit of the RA Capital Healthcare Fund, L.P. (the &quot;Fund&quot;), RA Capital Nexus II Fund, L.P. (the &quot;Nexus II Fund&quot;) and a separately managed account (the &quot;Account&quot;). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received from the option, which will offset advisory fees owed by the Fund, the Nexus II Fund and the Account to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock.</footnote>
    </footnotes>

    <ownerSignature>
        <signatureName>/s/ Zachary Scheiner</signatureName>
        <signatureDate>2024-03-25</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
